Molecular characterization of rpoB gene mutations in isolates from tuberculosis patients in Cubal, Republic of Angola
Rando-Segura, Ariadna (Hospital Universitari Vall d'Hebron)
Aznar, Maria Luisa (Hospital Universitari Vall d'Hebron)
Moreno, María Milagros (Hospital Nossa Senhora da Paz (Cubal, Angola))
Espasa, Mateu (Hospital Universitari Vall d'Hebron)
Sulleiro Igual, Elena (Hospital Universitari Vall d'Hebron)
Bocanegra García, Cristina (Hospital Universitari Vall d'Hebron)
Gil Olivas, Eva (Hospital Universitari Vall d'Hebron)
Nindia Eugénio, Arlete. (Hospital Nossa Senhora da Paz (Cubal, Angola))
Escartin Huesca, Carlos (Hospital Universitari Vall d'Hebron)
Zacarias, Adriano (Hospital Nossa Senhora da Paz (Cubal, Angola))
Vegue Collado, Josep (Hospital Universitari Vall d'Hebron)
Katimba, Domingos (Hospital Nossa Senhora da Paz (Cubal, Angola))
Vivas Cano, Maria Carmen (Hospital Universitari Vall d'Hebron)
Gabriel, Estevao (Hospital Nossa Senhora da Paz (Cubal, Angola))
López García, Maria Teresa (Hospital Nossa Senhora da Paz (Cubal, Angola))
Pumarola Suñé, Tomàs (Hospital Universitari Vall d'Hebron)
Molina Romero, Israel (Hospital Universitari Vall d'Hebron)
Tórtola Fernández, María Teresa (Hospital Universitari Vall d'Hebron)
Universitat Autònoma de Barcelona

Fecha:	2021
Resumen:	Background: The importance of Mycobacterium tuberculosis strains with disputed rpoB mutations remains to be defined. This study aimed to assess the frequency and types of rpoB mutations in M. tuberculosis isolates from Cubal, Angola, a country with a high incidence of tuberculosis. Methods: All isolates included (n = 308) were analyzed using phenotypic drug susceptibility testing and GenoType MTBDRplus assay. DNA sequencing of the rpoB gene and determination of rifampicin MIC by macrodilution method were additionally performed on isolates yielding discordant results (n = 12) and those in which the mutation detected was not characterized (n = 8). Results: In total, 85. 1% (74/87) of rifampicin-resistant strains had undisputed rpoB mutations -S450L (49), D435V (15), H445D (3), H445Y (2), Q432ins (1), L449M plus S450F (1), S450F (1), S450W (1) and S450Y (1)-; 10. 3% (9/87) had disputed rpoB mutations-L430P plus S493L (1), N437del (1), H445L (3), D435Y (2), L452P (2)-, 2. 3% (2. 3%) showed no rpoB mutations and 2. 3% (2/87) showed heteroresistance-D435Y plus L452P and L430P plus S493L-. Conclusion: Disputed rpoB mutations were common, occurring in 10. 3% of rifampicin resistant isolates. Current phenotyping techniques may be unable to detect this resistance pattern. To increase their sensitivity, a lower concentration of RIF could be used in these tests or alternatively, rpoB mutations could be screened and characterized in all M. tuberculosis strains.
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Angola ; Cubal ; GenoType MTBDRplus VER2.0 ; Resistance ; Rifampicin ; RpoB mutations
Publicado en:	BMC Infectious diseases, Vol. 21 Núm. 1 (december 2021) , p. 1056, ISSN 1471-2334

DOI: 10.1186/s12879-021-06763-8
PMID: 34641802

7 p, 858.2 KB

El registro aparece en las colecciones:
Artículos > Artículos de investigación
Artículos > Artículos publicados